Sugi Predict

Sugi Predict / Compounds / SCHEMBL1702115

SCHEMBL1702115

SCHEMBL1702115

COc1ccnc2cc(Cl)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ GAK O14976 2/20 0.61
▸ NPC1 O15118 1/20 0.58
▸ NR4A2 P43354 2/20 0.58
▸ SOS2 Q07890 1/20 0.58
▸ SRC P12931 1/20 0.55
▸ MAPT P10636 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ GLA P06280 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ POLB P06746 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ PRNP P04156 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7461008 0.88 NPC1 (0.58) LMNASMN1; SMN2GAKNPC1NR4A2
SCHEMBL7529202 0.87 NR4A2 (0.59) LMNASMN1; SMN2GAKNR4A2SOS2
SCHEMBL7461823 0.86 APP (0.58) LMNASMN1; SMN2GAA
SCHEMBL3242778 0.85 GAK (0.61) LMNASMN1; SMN2GAKNPC1NR4A2
SCHEMBL10377143 0.84 POLB (0.63) LMNASMN1; SMN2GAKNR4A2SOS2
SCHEMBL11130189 0.84 NR4A2 (0.61) LMNASMN1; SMN2GAKNR4A2SOS2
SCHEMBL13409356 0.83 LMNA (0.56) LMNASMN1; SMN2GAKNPC1NR4A2
SCHEMBL8543890 0.82 LMNA (0.49) LMNASMN1; SMN2GAKNPC1NR4A2
SCHEMBL7468546 0.82 KDR (0.56) LMNASMN1; SMN2MAPK1
SCHEMBL13481253 0.82 LMNA (0.55) LMNASMN1; SMN2GAKNR4A2SOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105037266-A Antibacterial chloroxoquinoline derivative WANG ZIHOU 2015-11-11 — — CN claimed
CN-105017145-A Chloroxoquinoline derivative with anti-tumor activity WANG ZIHOU 2015-11-04 — — CN claimed
CN-103864681-A Chloroxoquinoline derivatives for antibacterial use WANG ZIHOU 2014-06-18 — — CN claimed
CN-103864680-A Chloroxoquinoline derivative with antineoplastic activity WANG ZIHOU 2014-06-18 — — CN claimed
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING ABIVAX (FR) 2024-10-17 — — US disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 — — EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 — — US disclosed
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 — — EP disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 — — US disclosed
US-20220127253-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING ABIVAX (FR) 2022-04-28 — — US disclosed
CN-109776496-B Compounds for the treatment of premature aging and especially premature aging ABIVAX公司 2021-09-28 — — CN disclosed
CN-113004249-A Compounds for the treatment of premature aging and especially premature aging ABIVAX公司 2021-06-22 — — CN disclosed
WO-2006000085-A1 HEPATITIS C INHIBITOR PEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-05 — — WO disclosed
EP-1556356-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS Warner-Lambert Company LLC (US) 2005-07-27 — — EP disclosed
US-20040132772-A1 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis WARNER-LAMBERT COMPANY LLC 2004-07-08 — — US disclosed
EP-1435356-A1 Quinoline derivatives as CRTH2 antagonists Warner-Lambert Company LLC (US) 2004-07-07 — — EP disclosed
WO-2004043339-A2 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 — — WO disclosed
WO-2004035543-A1 TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-04-29 — — WO disclosed
EP-1413306-A1 Tetrahydroquinoline derivatives as CRTH2 antagonists Warner-Lambert Company LLC (US) 2004-04-28 — — EP disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132772-A1 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis HRH1, HRH2, HRH4 LMNA 2805/4885SMN1; SMN2 4792/4885GAK 1841/4885
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING RCOR1, NR3C1, NR5A1 LMNA 2362/4885SMN1; SMN2 3125/4885GAK 1556/4885
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 LMNA 3852/4885SMN1; SMN2 2224/4885GAK 2028/4885
US-20220127253-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING RCOR1, NR3C1, NR5A1 LMNA 2362/4885SMN1; SMN2 3125/4885GAK 1556/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 LMNA 3852/4885SMN1; SMN2 2224/4885GAK 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.